Volume 6, Issue 3 Special Edition, September 2015

Volume 6, Issue 3 Special Edition, September 2015



Monitoring deep response in chronic myeloid leukaemia: new methodologies and innovative technologies

Optimizing patient outcomes in CML

When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?

Inotuzumab ozogamicin (InO) shows promising efficacy and safety in ALL

Blinatumomab: new hope for patients with relapsed/refractory acute lymphoblastic leukemia

T. Feys

Driver mutations and their evolution in CLL

Venetoclax-rituximab induces deep responses in relapsed CLL

Advances in Acute Myeloid Leukaemia: Increased insights in chemoresistance and first randomised evidence for kinase inhibition

Highlights in Non-Hodgkin’s Lymphoma

Prevention of febrile neutropenia with prophylactic G-CSF improves outcome

Immunotherapy: a new era in the management of lymphoma and multiple myeloma?

Nivolumab is safe and effective in patients with relapsed/refractory lymphoid malignancies and classical Hodgkin lymphoma

Multiple myeloma is different in elderly patients

Adding elotuzumab to standard treatment for multiple myeloma delays disease progression

Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma

Luspatercept increases hemoglobin and decreases the transfusion need in patients with low-, and intermediate-1 myelodysplastic syndrome

JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis

New treatment options for patients with inadequately controlled polycythemia vera

Management of thrombosis in Paroxysmal Nocturnal Hemoglobinuria

Polyphosphate, a modulator of hemostasis and thrombosis: a novel target for antithrombotic agents?

New genetic variants in GFI1B discovered in patients with bleeding and platelet disorders

Longer acting agents for the treatment of bleeding disorders